Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma - Wikidata - wikimedia - TriplyDB

Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma

Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma

http://www.wikidata.org/entity/Q33761751

about

Management of hepatocellular carcinoma in the elderly In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors Hospital-based, acute care encounters after radiofrequency ablation of hepatic tumours Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.Comparative assessment of the safety and effectiveness of radiofrequency ablation among elderly medicare beneficiaries with hepatocellular carcinoma.Molecular imaging of hepatocellular carcinoma xenografts with epidermal growth factor receptor targeted affibody probes Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008.Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma Hepatocellular carcinoma: MR staging and therapeutic decisions.Liver resection combined with local ablation: where are the limits?Ultrasound-guided intratumoral delivery of doxorubicin from in situ forming implants in a hepatocellular carcinoma model.Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology.Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study.National trends in surgical procedures for hepatocellular carcinoma: 1998-2008.Assessment of non-surgical versus surgical therapy for localized hepatocellular carcinoma.Ethanol injection therapy for small hepatocellular carcinomas located beneath a large vessel using a curved percutaneous ethanol injection therapy needle.Intracavitary contrast-enhanced ultrasound in abscess drainage--feasibility and clinical value.Short-term outcomes of ablation therapy for hepatic tumors: evidence from the 2006-2009 nationwide inpatient sample.Transarterial chemoembolization as first-line therapy for hepatocellular carcinomas infeasible for ultrasound-guided radiofrequency ablation: a retrospective cohort study of 116 patients.Thermal necrosis induced by electrocauterization as a local adjuvant therapy in local aggressive bone tumors, what is the safe limit for surgical margins? An experimental study.Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an Italian in-field experience.Early Stage Hepatocellular Carcinomas Not Feasible for Ultrasound-Guided Radiofrequency Ablation: Comparison of Transarterial Chemoembolization Alone and Combined Therapy with Transarterial Chemoembolization and Radiofrequency Ablation.

P2860

Q26827161-E5293AD8-2CC1-4C3F-BADC-038F5F36BF27 Q30372076-1DEDC20D-9A89-44CD-BAEA-8539667B1D3B Q33716634-9AFC3EBC-54DF-4E6D-9199-8FD9D20DA5EC Q34156818-9D149978-8873-4A1B-9D92-C113B820582C Q34675546-DF92252F-7173-4F22-B976-3C92502C1E21 Q35187951-15B8150C-9710-45ED-9F9E-2C97AF816D7D Q35690995-358BAFE3-86E3-4D54-88F3-519B92EA133E Q36845960-B2A4B6EA-933B-4948-BCCB-18232F700110 Q37403255-92AE099E-73CC-4E61-A0D4-04D991499D17 Q37698565-473C520B-041A-4B9C-A123-42FBCF556E0C Q37709406-29BEED33-C1B6-42BB-8776-C6EA157059FE Q37863539-2490ECD5-13BA-4BDA-AFAB-9C7A13FB7A87 Q37871748-D372FB7E-93F1-4656-969E-E93B8F65F6A2 Q38783457-5C62E84A-69BD-4D8B-9492-555B475B9AF1 Q39410889-F7D559E8-8043-4941-9D72-B4CAF9A0F369 Q39466409-0E2ADD6E-0545-43F3-989E-BF6A9A02195D Q40003430-5E2B4B8C-78B5-4FE7-B1B3-BB534B138407 Q40216373-A4058127-EDA1-4494-ADC8-A8CC7C29731A Q40452297-767BAE9A-90AC-4D55-98BC-3D870D1B393A Q41112269-DEDB5AE4-4B1E-4BCE-AED9-D9A9E2C907CF Q42648531-5A49DB1C-D202-43B4-991E-1E9D3A143A8C Q44441828-8C76D368-E8D7-4CF6-8309-FBF22E8D9C43 Q52934495-231D7700-F07D-4E0C-A805-1F294E16755C Q53391931-7DF936FF-6112-4FE2-97BC-614FBFE95B87 Q53394233-6C2AB612-0FF3-49A5-B5DD-ADDAC9483E69

P2860

Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma

http://www.wikidata.org/entity/Q33761751

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Trends in the utilization and ...... n for hepatocellular carcinoma

@ast

Trends in the utilization and ...... n for hepatocellular carcinoma

@en

type

label

Trends in the utilization and ...... n for hepatocellular carcinoma

@ast

Trends in the utilization and ...... n for hepatocellular carcinoma

@en

prefLabel

Trends in the utilization and ...... n for hepatocellular carcinoma

@ast

Trends in the utilization and ...... n for hepatocellular carcinoma

@en

P1433

Q33761751-323783D8-D0F5-4B73-B4C4-5156E9575A72

P1476

Q33761751-AB273442-742A-4AC6-A322-62009D67B6BD

P2093

Q33761751-13C63D39-FBED-4731-A909-540554A67229

Q33761751-3E40DED4-FC9B-4267-B379-C11AB26ADD52

Q33761751-6BA3D729-D09E-4BED-8E9C-01E3F07247AB

Q33761751-941596FF-3C62-4053-BAA6-7965BE4FC032

Q33761751-C6CA689D-9DF4-496C-AC43-1D8AE75C40F8

Q33761751-E09DF03E-0FE1-4339-BDF0-2AE9CFB8F0F0

Q33761751-E290D1CE-0F6B-4379-AB36-9D48A4CDE67A

Q33761751-FA6E9BCD-94F0-4CCD-990F-1F128B80C02F

P2860

Q33761751-04BD5309-B4DD-46F8-A53B-6CFD9D19582B

Q33761751-0751ACB6-5187-41EF-A30C-DC5DE0349CDA

Q33761751-1481378C-E4F0-40B9-98CD-677573D42DEE

Q33761751-23A9D8A3-5704-4ECB-B191-76A850F7E6D6

Q33761751-2BBE75AB-DBC0-49CE-9567-1A04E1A3D94C

Q33761751-35A9ADDE-C2C0-4911-AC34-75518F16C997

Q33761751-3DCEAFDA-1742-4DB6-99AF-E9EC5EFF3935

Q33761751-3EE49AE3-1BE8-43C5-8D32-BB397DA6462B

Q33761751-3F22746A-09AC-4418-A0C7-F142381C9FC6

Q33761751-4157E112-1604-415F-8EE7-854AE62EFE34

P304

Q33761751-015EF1FC-B9C0-4553-8AAD-B6898E635AA8

P31

Q33761751-1A1CB8BF-6BD6-4E24-8A8A-C9B4ADE6B820

P356

Q33761751-B10BBCA9-161B-4165-8CA5-30460DA5E242

P433

Q33761751-6689B54F-8296-4625-A261-72E23F741C46

P478

Q33761751-56D26B92-2507-460F-BF20-DADE98D372F8

P577

Q33761751-E3BE17FB-0F37-4F81-9639-5CD3978518DD

P5875

Q33761751-3F98387B-B17E-44FD-BF59-9346310A96D1

P698

Q33761751-3DF5B99D-1A01-4F76-84DD-2EC294A52DDE

P932

Q33761751-C7155474-C1D5-4A6D-8EB9-566EEE3F7825

P356

J.JAMCOLLSURG.2009.12.026

P1433

Journal of the American College of Surgeons

P1476

Trends in the utilization and ...... n for hepatocellular carcinoma

@en

P2093

David R Flum

http://www.w3.org/2001/XMLSchema#string

Farhood Farjah

http://www.w3.org/2001/XMLSchema#string

James O Park

http://www.w3.org/2001/XMLSchema#string

Laura-Mae Baldwin

http://www.w3.org/2001/XMLSchema#string

Nader N Massarweh

http://www.w3.org/2001/XMLSchema#string

Raymond S W Yeung

http://www.w3.org/2001/XMLSchema#string

Rebecca Gaston Symons

http://www.w3.org/2001/XMLSchema#string

Thomas L Vaughan

http://www.w3.org/2001/XMLSchema#string

P2860

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study.

Global cancer statistics in the year 2000.

Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations.

Who oversees innovative practice? Is there a structure that meets the monitoring needs of new techniques?

New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients.

P304

441-448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JAMCOLLSURG.2009.12.026

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

210

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42610459

http://www.w3.org/2001/XMLSchema#string

P698

20347736

http://www.w3.org/2001/XMLSchema#string

P932

2847589

http://www.w3.org/2001/XMLSchema#string